|Year : 2009 | Volume
| Issue : 2 | Page : 111-115
Quantitation of hepatitis B virus DNA in plasma using a sensitive cost-effective "in-house" real-time PCR assay
Hubert Darius J Daniel1, John G Fletcher1, George M Chandy2, Priya Abraham1
1 Department of Clinical Virology, Christian Medical College, Vellore - 632 004, India
2 Department of Clinical Gastroenterology, Christian Medical College, Vellore - 632 004, India
|Date of Submission||02-Apr-2008|
|Date of Acceptance||07-Sep-2008|
Department of Clinical Virology, Christian Medical College, Vellore - 632 004
Source of Support: None, Conflict of Interest: None
Background: Sensitive nucleic acid testing for the detection and accurate quantitation of hepatitis B virus (HBV) is necessary to reduce transmission through blood and blood products and for monitoring patients on antiviral therapy. The aim of this study is to standardize an "in-house" real-time HBV polymerase chain reaction (PCR) for accurate quantitation and screening of HBV. Materials and Methods: The "in-house" real-time assay was compared with a commercial assay using 30 chronically infected individuals and 70 blood donors who are negative for hepatitis B surface antigen, hepatitis C virus (HCV) antibody and human immunodeficiency virus (HIV) antibody. Further, 30 HBV-genotyped samples were tested to evaluate the "in-house" assay's capacity to detect genotypes prevalent among individuals attending this tertiary care hospital. Results: The lower limit of detection of this "in-house" HBV real-time PCR was assessed against the WHO international standard and found to be 50 IU/mL. The interassay and intra-assay coefficient of variation (CV) of this "in-house" assay ranged from 1.4% to 9.4% and 0.0% to 2.3%, respectively. Virus loads as estimated with this "in-house" HBV real-time assay correlated well with the commercial artus HBV RG PCR assay ( r = 0.95, P < 0.0001). Conclusion: This assay can be used for the detection and accurate quantitation of HBV viral loads in plasma samples. This assay can be employed for the screening of blood donations and can potentially be adapted to a multiplex format for simultaneous detection of HBV, HIV and HCV to reduce the cost of testing in blood banks.
Keywords: Hepatitis B virus quantitation, real-time polymerase chain reaction
|How to cite this article:|
Daniel HJ, Fletcher JG, Chandy GM, Abraham P. Quantitation of hepatitis B virus DNA in plasma using a sensitive cost-effective "in-house" real-time PCR assay. Indian J Med Microbiol 2009;27:111-5
|How to cite this URL:|
Daniel HJ, Fletcher JG, Chandy GM, Abraham P. Quantitation of hepatitis B virus DNA in plasma using a sensitive cost-effective "in-house" real-time PCR assay. Indian J Med Microbiol [serial online] 2009 [cited 2020 May 31];27:111-5. Available from: http://www.ijmm.org/text.asp?2009/27/2/111/45362
| ~ Introduction|| |
Despite the wide availability of good hepatitis B surface antigen (HBsAg)-based detection systems for hepatitis B virus (HBV), there is evidence that transmission of HBV through blood and blood products occurs during the serological window period and more importantly during the later stages of infection due to occult hepatitis B infection.  Individuals negative for HBsAg but positive for HBV DNA in blood or tissues with or without the presence of HBV antibodies are categorized as occult HBV infection.  In a recent study done from 2001 to 2006 in 93 Italian transfusion centers screening 34,05,497 units, a positivity of 57.8 per million donations with a viral load range of 6 to 3,340 IU/mL was reported (Velati et al. , Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey, 2008-in press). Occult HBV infection was detected in 13-71% of liver tissues and in 5-55% of serum from chronic liver disease patients negative for HBsAg and hepatitis C virus antibody (HCV-Ab). , Individuals with occult HBV infection have been shown to be infectious to immunocompromised individuals, especially from organ donors.  HBV DNA detection in blood banks can therefore reduce the transfusion risk from individuals with such occult HBV infection or variants of HBV, which may escape detection by the existing serological screening methods. 
| ~ Materials and Methods|| |
This study included patients with chronic HBV infection who were referred from the departments of Gastroenterology, Nephrology and Haematology to the clinical virology department for purposes of blood collection. All patients were recruited after a verbal consent in addition to a general consent that was obtained for all investigations as part of our routine patient management in this hospital. Blood was collected in tubes containing 0.5% ethylene diammine tetraacetic acid. Plasma was separated from whole blood collected from 30 individuals with chronic HBV infection after centrifugation at 1500rpm for 10 minutes at 4° C and stored in multiple aliquots at −60° C until time of testing. All the chronically HBV infected individuals were screened for HBsAg (DiaSorin S.p.A., Italy) and HBeAg (DiaSorin S.p.A., Italy). In addition, blood samples were also collected from 70 donors at the Ida Scudder blood bank in this tertiary care centre. All donors were negative for antibody to human immunodeficiency viruses (HIVs) 1 and 2, HBsAg and HCV-Ab. The blood donor samples were not screened for anti-HBcAg IgG or IgM as this is not included in the donor screening in this blood bank. Blood was collected from the first 10 donors reporting for the day (monday through friday, except on holidays) after completion of the donor's questionnaire and physical examination. Samples were coded and the identity blinded to the person performing the assay.
In addition, 10 plasma samples each from HIV-1 and HCV RNA-positive chronically infected individuals were also tested. Samples with simulated dual infection containing HBV DNA and HIV-1 or HCV RNA ( n = 5) and simulated triple infection containing HBV DNA, HIV-1 RNA and HCV RNA ( n = 5) were also tested. Two hundred microlitres each of HBV DNA, HIV-1 RNA and HCV RNA positive samples with viral load ranging from 10 8 to 10 5 IU/mL for HBV DNA, 10 6 to 10 4 IU/mL for HIV-1 and HCV RNA were taken and mixed at different combinations to simulate dual or triple infection. For simulated dual infection samples, 200µl of negative plasma was added to make up the volume to 600µl of samples.
"In-house" HBV PCR assay
Nucleic acid extraction
HBV DNA was extracted from plasma samples using the QIAamp MinElute virus spin kit (Qiagen GmbH, Hilden, Germany). A sample volume of 200µL was used for the extraction as per manufacturer's instruction. Nucleic acid was eluted in 60µL elution buffer provided by the manufacturer.
The probe for the detection of HBV DNA was labeled with reporter dye (ROX) at the 5′ end and with black hole quencher as the non-fluorescent quencher at the 3′ end (Operon Biotechnologies GmbH, Cologne, Germany). The primer and probe sequences are shown in [Table 1]. Primer and probe sequences were kindly provided by Prof. Richard Tedder (University College London, London, UK). The specificity of the primers and probe were checked using the BLAST search. This search indicated that the primer and probe set had the capacity to detect all HBV genotypes (A-H). Amplification was performed using 10µL of extract in a 25µl volume containing 12.5µL of 2X QuantiTect Multiplex RT-PCR NoROX buffer and 10 pm each of HBV primers (HBV TAQ 1, HBV TAQ 2) and 10pm of HBV probe (HBV TAQ PR). The reaction mixture was amplified using the following thermal cycling conditions: 50° C for 30 min followed by 95° C for 15 min and 45 cycles at 95° C for 45s and 60° C for 75s. Amplification and detection of HBV DNA was performed using the Rotor-Gene TM 3000. Standard curves were generated using the in-built software (Rotor-Gene version 6.0) in the Rotor-Gene 3000. The assay described here is adapted from the previously published work. 
Artus HBV RG PCR (commercial) assay
Nucleic acid extraction
HBV DNA isolation was also performed using the QIAamp Blood mini kit as per the manufacturer's instructions. A sample volume of 200µL was used for extraction. Elution was performed using 50µL of AVE buffer (provided by the manufacturer).
This assay amplified a 134 bp region of the HBV genome that was detected by the cycling A.FAM channel. This assay uses an internal control that was detected by the cycling A.JOE channel. All the five standards provided by the manufacturer were pre-extracted. Amplification and detection of HBV DNA was performed using the Rotor-Gene 3000 as per the manufacturer's instructions. Standard curves were generated using the in-built software (Rotor-Gene version 6.0). A sample result is accepted only when the internal control is amplified.
This "in-house" real-time PCR was further evaluated for its capacity to detect the various genotypes prevalent among individuals seen in this tertiary care centre. HBV genotyping was performed using PCR-RFLP as standardized in this laboratory. 
HBV "in-house" standard
The "in-house" standard was made from a clinical HBV DNA-positive sample. This was vortexed, aliquoted and stored at −60° C. This standard was run in parallel with the WHO international standard for HBV DNA 97/746 from the National Institute for Biological Standards and Control (NIBSC, UK) to assess the HBV viral load. This "in-house" standard was further validated by testing it in triplicate in three different assays.
| ~ Results|| |
Calibration of the "in-house" standard against the WHO international standard for HBV DNA 97/746
The viral load of the "in-house" standard as assessed using the WHO standard was estimated to be 10 8 IU/mL. Ten-fold dilutions of this HBV standard were made down to 10IU/mL using normal human plasma and dilutions from 10 6IU/mL to 10IU/mL were tested in all the runs to generate the standard curve.
Sensitivity (lower limit of detection)
Log dilutions of the WHO international standard for HBV DNA 97/746 for HBV DNA were performed to assess the analytical sensitivity of this "in-house" HBV real-time assay. The lower limit of detection of this assay as assessed by the second WHO international standard for HBV DNA 97/746 was 50 IU/mL.
Seventy blood donor samples that were negative for HBsAg were negative by this "in-house" assay. Ten samples each that were positive for HIV-1 and HCV RNA were also negative in this HBV real-time assay. HBV DNA in five samples each of the simulated dual infection (HBV with HCV or HIV-1) and triple infection (HCV, HBV and HIV-1) were also correctly identified.
The intra-assay reproducibility of this "in-house" HBV real-time PCR was calculated with triplicate testing of three plasma samples with different concentrations of HBV DNA load (low, medium and high) in the same run. The intra-assay CV ranged from 0.0% to 2.3% [Table 2] and the interassay CV ranged from 1.4% to 9.4% [Table 3]. The intra-assay and interassay CV for this assay using actual copy numbers ranged from 1.2 to 19.7 and 5.3 to 22.7, respectively.
Correlation between artus HBV RG PCR real-time assay
The viral loads of the 30 patients as per this "in - house" HBV real-time PCR assay was compared with the artus HBV RG PCR assay and the correlation coefficient was 0.95 ( P < 0.0001, 95% CI for r 0.90-0.98) [Figure 1]. The Bland-Altman plot showing the comparison of the two assays is shown in [Figure 2]. The HBV viral DNA loads used for comparison ranged from 341IU/mL to 7.6 × 10 7IU/mL. Among the 30 samples compared, two samples gave identical results while 25 samples gave a higher viral load (log difference in viral loads ranged from 0.1 to 2.3Log IU/mL) and three samples gave lower viral loads (log difference in viral loads ranged from 0.1 to 0.3 Log IU/mL) compared with the artus HBV RG PCR real-time assay.
The serological profile of the thirty patients samples are given in [Table 4]. All the samples were HBsAg positive. The correlation coefficient for HBeAg positive and negative samples compared between the artus and the in-house assay were 0.91 and 0.96 respectively.
Detecting HBV genotypes prevalent in this region
The HBV genotypes tested include HBV genotype A ( n = 6), D ( n = 19) and C ( n = 5). These "in-house" HBV assays detected all the tested genotypes prevalent in this region.
| ~ Discussion|| |
We describe an "in-house" real-time PCR that quantitates plasma HBV DNA in infected individuals with good accuracy. This assay has excellent analytical sensitivity with a good dynamic range for detection of HBV DNA.
For quantitation of HBV DNA there are a variety of commercial assays available that are routinely used in diagnostic laboratories. Most commercial quantitative assays have a limited dynamic range. Hence, clinical samples may need to be diluted and retested to get the exact viral load. This "in-house" HBV real-time PCR assay exhibits a wide dynamic range of approximately 10 8IU/mL and hence samples do not have to be diluted and retested. The lower detection limit of this assay is 50IU/mL. Given these results, the assay may be adapted to a pool-testing format for large-scale screening as in blood banks and transfusion centres.
In order to compare the viral load results generated from different laboratories, it is essential to have validated, internationally acceptable standards. We have therefore used the WHO standard of HBV to calibrate an internal standard that was used to quantitate the viral load of the samples, which was expressed in IU/mL. Using this "in-house" standard, the viral load of the samples was compared with a commercial real-time assay. The "in-house" HBV real-time assay showed excellent correlation ( r = 0.95, P < 0.0001) with the commercial assay.
In this study, two different methods of extraction were used for the "in-house" real-time assay and the artus commercial assay. The QIAamp MinElute virus spin kit used for extraction of HBV DNA in the "in-house" real-time PCR assay was used to improve the sensitivity of the assay and with a view to use this extraction method for both RNA and DNA extraction. A small difference in efficiency may exist between both extraction methods used.
This "in-house" assay exhibited very low interassay and intra-assay variation, which is a basic requirement of a good quantitation assay. Further, fine tuning of this assay would make it highly satisfactory as a screening assay.
This assay uses primer and probe from the conserved region of the surface gene of HBV. Recent studies have shown the surface gene PCR-based assays to be efficient and sensitive compared with the core and 'X' regions of HBV.  Another study compared the COBAS AMPLICOR monitor with an "in-house" real-time PCR amplifying the surface gene. This study reported that the COBAS AMPLICOR monitor assay failed to recognize increasing levels of viraemia in individuals on treatment due to core mutations that develop during treatment. 
This assay, which uses the manual nucleic acid extraction protocol and the real-time Taqman chemistry, is very sensitive and can potentially be used to detect occult HBV infection. The total assay duration is 5.5-6 hours, including the extraction protocol. The assay has only a single round of amplification with a better sensitivity compared with conventional nested PCR. The assay is easy to perform and can be used for high-throughput screening. Further, because this is a non-nested PCR, cross contamination, which is inherent to all conventional nested PCR, could be avoided. This assay was able to detect all the HBV genotypes prevalent in this region. Since this assay does not have an internal control, it cannot confirm a true negative sample, which is similar to conventional PCR. This "in-house" assay is considerably inexpensive compared with the commercial quantitative HBV real-time PCR assays currently available. A rough estimate of the cost of this "in-house" assay amounts to less than 50% of the commercial real-time assay.
In summary, this "in-house" real-time HBV quantitative assay could have wide applications in diagnostic laboratories and blood banks.
| ~ Acknowledgement|| |
This study was done using intramural funds from departmental resources. We gratefully thank Prof. G. Sridharan, Department of Clinical Virology, for his generous advice during standardization of the assay and valuable inputs during the preparation of this manuscript.
| ~ References|| |
|1.||Kim SM, Lee KS, Park CJ, Lee JY, Kim KH, Park JY, et al . Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. J Infect 2007;54:185-91. [PUBMED] [FULLTEXT]|
|2.||Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002;9:243-57. [PUBMED] [FULLTEXT]|
|3.||Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002;2:479-86. [PUBMED] [FULLTEXT]|
|4.||Ghisetti V, Marzano A, Zamboni F, Barbui A, Franchello A, Gaia S, et al . Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: Clinical significance. Liver Transpl 2004;10:356-62. [PUBMED] [FULLTEXT]|
|5.||Allain JP. Occult hepatitis B virus infection: Implications in transfusion. Vox Sang 2004;86:83-91. [PUBMED] [FULLTEXT]|
|6.||Garson JA, Grant PR, Ayliffe U, Ferns RB, Tedder RS. Real-time PCR quantitation of hepatitis B virus DNA using automated sample preparation and murine cytomegalovirus internal control. J Virol Methods 2005;126:207-13. [PUBMED] [FULLTEXT]|
|7.||Vivekanandan P, Abraham P, Sridharan G, Chandy G, Daniel D, Raghuraman S, et al . Distribution of hepatitis B virus genotypes in blood donors and chronically infected patients in a tertiary care hospital in southern India. Clin Infect Dis 2004;38:e81-6. [PUBMED] [FULLTEXT]|
|8.||Lu YQ, Han JX, Qi P, Xu W, Zu YH, Zhu B. Rapid quantification of hepatitis B virus DNA by real-time PCR using efficient TaqMan probe and extraction of virus DNA. World J Gastroenterol 2006;12:7365-70. [PUBMED] [FULLTEXT]|
|9.||Lindh M, Hannoun C, Malmstrφm S, Lindberg J, Norkrans G. Lamivudine resistance of hepatitis B virus masked by coemergence of mutations in probe region of the COBAS AMPLICOR assay. J Clin Microbiol 2006;44:2587-9. |
[Figure 1], [Figure 2]
[Table 1], [Table 2], [Table 3], [Table 4]
|This article has been cited by|
||Performance of two real-time PCR assays for hepatitis B virus DNA detection and quantitation
| ||Dramane Kania,Laure Ottomani,Nicolas Meda,Marianne Peries,Pierre Dujols,Karine Bolloré,Wendy Rénier,Johannes Viljoen,Jacques Ducos,Philippe Van de Perre,Edouard Tuaillon |
| ||Journal of Virological Methods. 2014; 201: 24 |
|[Pubmed] | [DOI]|
||Molecular methods in the diagnosis and management of chronic hepatitis B
| ||Perumal Vivekanandan, Om Vir Singh |
| ||Expert Review of Molecular Diagnostics. 2010; 10(7): 921 |
|[VIEW] | [DOI]|
||Nuclease-resistant double-stranded DNA controls or standards for hepatitis B virus nucleic acid amplification assays
| ||Meng, S., Zhan, S., Li, J. |
| ||Virology Journal. 2009; 6(art no 226) |